Structure Therapeutics

News

Generic semaglutide in India, and other weight-loss news

Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.

News

Measuring tape overlain on a dark yellow background

Pfizer's $2bn+ obesity bet, and other weight-loss news

Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

News

Buoyed by new obesity data, Structure files $476m offering

Riding high from positive clinical trial results for its oral weight-loss therapy, Structure Therapeutics has filed a public offering that it hopes will raise $476 million

Generic semaglutide in India, and other weight-loss news

Pfizer's $2bn+ obesity bet, and other weight-loss news

Buoyed by new obesity data, Structure files $476m offering

Late-breakers to look out for at ASCO 2026

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks